The importance of anti-MDA5 antibody in the prognosis of myositis has been described by Tanizawa et al. (16), who showed that anti-MDA5 was an independent determinant of overall mortality in DM/PM patients with ILD. Here, IFIH1 is linked to dermatomyositis.